The main objective of a carcinogenicity testing is to identify the tumorigenic potential of drugs and medical devices in test animals in order to assess their relevant risk in humans. VIMTA offers 2-year carcinogenicity studies in rats and mice by oral gavage, and also offers studies for topical and parenteral administration as appropriate for the expected human dosing route. Our study designs for carcinogenicity studies are primarily in accordance with the guidelines published by the ICH, however we can also perform studies to comply with the regulatory requirements of US-FDA, JMHW and CPMP (for Europe).